Document is current

Article History

Received: 2 October 2024

Revised: 7 October 2024

Accepted: 17 October 2024

First Online: 21 November 2024

Competing interests

: KN: None. MP: None. LT: None. YCT: None. TYW: Professor Wong is a consultant for Astellas, Bayer, Boehringer-Ingelheim, Genentech, Iveric Bio, Novartis, Oxurion, Plano, Roche, Sanofi, and Shanghai Henlius. He is an inventor, holds patents and is a co-founder of start-up companies EyRiS and Visre, which have interests in, and develop digital solutions for eye diseases. DHS: Consultant: Gyroscope, Roche, Alcon, BVI; Research funds: Alcon, Bayer, DORC, Gyrsocope, Boehringer-Ingelheim. MRM: Consultant for Abbvie, Allergan, Apellis, Alimera, Bayer, Zeiss, Lumithera, Novartis, Oculis, Ocuterra, Gensight Therapeutics, RetinAI, Isarna Therapeutics, Kubota, Roche, Böhringer-Ingelheim, Dandelion, Eyepoint, Iveric Bio. CW: Dr. Wykoff reported consulting for 4DMT, AbbVie, Adverum, Alcon, Alimera, Alkeus, Annexon, Apellis, Aviceda, Bayer, Biocryst, Boehringer Ingelheim, Clearside, EyeBiotech, EyePoint, Genentech, InGel, Janssen, Kiora, KodiakMerck, Neurotech, Novartis, Ocuphire, ONL, Opthea, Osanni, Panther, Perceive Bio, Ray, Regeneron, RegenXBio, Sanofi, Santen, Stealth, Valo, Zeiss. VC: Dr. Chaudhary reports acting as an advisory board member, grants and other from Novartis; acting as an advisory board member, grants and other from Bayer; grants from Allergan; acting as an advisory board member and grants from Roche; acting as an advisory board member for Janssen; acting as an advisory board member for Apellis; and acting as an advisory board member for Boehringer Ingelheim outside the submitted work. Dr. Chaudhary is also a current member of the Eye editorial board.

Free to read: This content has been made available to all.